OnKure Therapeutics, Inc.
OKUR · NASDAQ
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Valuation | ||||
| PEG Ratio | -0.04 | -0.31 | 0.12 | -0.02 |
| FCF Yield | -44.60% | -15.71% | -9.04% | -24.61% |
| EV / EBITDA | -0.10 | -5.53 | -10.21 | -0.77 |
| Quality | ||||
| ROIC | -51.84% | -127.95% | -270.31% | -26.94% |
| Gross Margin | 0.00% | 0.00% | 0.00% | 0.00% |
| Cash Conversion Ratio | 0.97 | 0.98 | 0.91 | 0.96 |
| Growth | ||||
| Revenue 3-Year CAGR | – | – | – | -100.00% |
| Free Cash Flow Growth | -47.07% | -23.87% | 26.44% | -105.72% |
| Safety | ||||
| Net Debt / EBITDA | 2.12 | 0.84 | 0.37 | 3.14 |
| Interest Coverage | -181.29 | 0.00 | 0.00 | 0.00 |
| Efficiency | ||||
| Inventory Turnover | 0.00 | 0.00 | 0.00 | 0.00 |
| Cash Conversion Cycle | -1,636.44 | -2,227.15 | -1,738.75 | 0.00 |